News
Wednesday, November 20th, 2013
Springer: December 2013 Aims/hypothesis We tested the hypothesis that age younger than 65 years at type 2 diabetes diagnosis is associated with worse subsequent glycaemic control. Methods A cross-sectional analysis of data from participants in the 2005–2010 National Health and Nutrition Examination Survey was performed. For adults with self-reported diabetes, we dichotomised age at diabetes diagnosis as […]
News
Wednesday, November 20th, 2013
NIH: November 14, 2013 Diabetes does not strike a person alone. It strikes families and communities. It strikes our nation and the world. During today’s World Diabetes Day and National Diabetes Month this November, we at the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, renew our […]
News
Wednesday, November 20th, 2013
Informa Healthcare: November 13, 2013 Insulin and incretin agents (dipeptidyl peptidase-4 inhibitors [DPP4is] and glucagon-like peptide-1 receptor agonists [GLP1 RAs]) are second-line treatment options in patients with type 2 diabetes (T2D) not achieving glycemic targets with metformin. Combinations of insulin with incretin agents have been explored in randomized controlled trials (RCTs) and retrospective studies. However, the […]
News
Wednesday, November 20th, 2013
Diabetes Spectrum: November 2013 This article addresses modern patients’ insatiable need for information as they make daily choices in managing diabetes. It introduces the resources available to diabetes patients and caregivers against the backdrop of the limitations medical practices face in meeting patients’ information and support needs. Social media are described, along with ways in which […]
News
Wednesday, November 20th, 2013
Diabetes Spectrum: November 2013 The advance of the Patient Protection and Affordable Care Act (ACA) and impending shortages of health care providers to serve the ever-increasing diabetes population have led to an increased need to do more with less in the field of health care. New and emerging technologies are making telehealth more accessible, more desirable, […]
Minority Diabetes Reports
Wednesday, November 13th, 2013
The Lancet Diabetes & Endocrinology: 11/12/13 Background Individuals of south Asian origin have a very high risk of developing type 2 diabetes compared with white Caucasians. We aimed to assess volume and activity of brown adipose tissue (BAT), which is thought to have a role in energy metabolism by combusting fatty acids and glucose to produce […]
Clinical Trial News
Wednesday, November 13th, 2013
Clin Trials: November 11, 2013 Background The Trial to Reduce Insulin Dependent Diabetes Mellitus in the Genetically at Risk (TRIGR) is the first multicenter international type 1 diabetes (T1D) prevention trial to be undertaken. A unique feature of TRIGR has been recruitment of eligible pregnant women and enrollment of newborns for long-term follow-up assessments. Purpose Our purpose is […]
Clinical Trial News
Wednesday, November 13th, 2013
Informa Healthcare: November 11, 2013 Previous studies have raised concerns around the transparency and disclosure rates of clinical trial results on clinical trial registries and in the scientific literature. The objective of this study was to assess the timely disclosure in the public domain of results of company-sponsored clinical trials related to all new medicines approved […]
Clinical Trial News
Wednesday, November 13th, 2013
Diabetes Care: November 6, 2013 Objective To utilize continuous glucose monitoring (CGM) to evaluate the impact of the novel, long-acting basal insulin analog LY2605541 on hypoglycemia and glycemic variability in patients with type 2 diabetes. Research design and methods Hypoglycemia and glucose variability were assessed with CGM of interstitial glucose (IG) in a subset of patients with type […]
Clinical Trial News
Wednesday, November 13th, 2013
Diabetes: November 1, 2013 DPP-4 inhibitors prevent degradation of incretin hormones (GLP-1 and GIP) while metformin may increase GLP-1 levels. We examined, in a 4-period cross-over trial, the influence of metformin (2000 mg/d), sitagliptin (100 mg/d), or their combination, on GLP-1 responses and on the incretin effect in 20 patients with type 2 diabetes comparing an […]
